Imbalance of oxidative stress and its role in Parkinson's disease
Ahmed H. AL-Hamdani
Abstract
Parkinson's disease (PD) is the greatest shared neurodegenerative disease affecting millions of individuals in the world, and it is linked to the continual deterioration of dopaminergic neurons in the Substantia nigra (SN) pars compacta. Despite years of intensive study, the detailed molecular mechanism underlying neuronal loss has not been fully elucidated. Taken together, these findings highlight that oxidative stress is a state of disturbed equilibrium between the creation of reactive oxygen species (ROS) and the activity of antioxidant defense systems within the cells as a key player in triggering and maintaining PD pathology. This review is a systematic one in line with the PRISMA statement. We examined the Scopus, PubMed, and Web of Science records for published articles in peer-reviewed journals from January 2000 to December 2024. Studies were eligible if they were case-control, cross-sectional, or cohort designs with human subjects, and participants had a confirmed PD diagnosis. In total, 47 articles fulfilling the criteria were included, involving 3,812 PD cases and 2,960 healthy controls. Patients with PD had remarkably increased malondialdehyde and 4-HNE levels, decreased superoxide dismutase and GPx activity, along with a 52.0% reduction in glutathione in SN. High 8-OHdG was significantly linked with UPDRS motor scores (r = 0.61; p < 0.001). There is a strong implication of oxidative stress in the development of PD, and a substantial amount of data supports its involvement in dopaminergic neurodegeneration and α-synuclein toxicity. Peripheral oxidative markers appear to have utility for diagnosis and prognosis. Therapeutic intervention in antioxidant pathways may serve as a potential disease-adapting strategy.
Keywords
References
- Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx. 2004; 1(1): 139-154. doi: 10.1602/neurorx
- Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Movement Disorders. 2013; 28 (1): 41-50. doi: 10.1002/mds.25095
- Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Movement Disorders. 2011; 26(6): 1049-1055. doi: 10.1002/mds.23732
- Zhu J, Chu CT. Mitochondrial dysfunction in Parkinson’s disease. Journal of Alzheimer's Disease. 2010; 20(Suppl 2): S325- S334. doi: 10.3233/JAD-2010-100363
- Parker WD, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson’s disease frontal cortex. Brain Research. 2008; 16: 215-218. doi: 10.1016/j.brainres.2007.10.061
- Jenner P, Olanow W. The pathogenesis of cell death in Parkinson’s disease. Neurology. 2006; 66(10 Suppl 4): S24-36. doi: 10.1212/wnl.66.10_suppl_4.s24
- Beal MF. Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology. 2005; 58(4): 495-505. doi: 10.1002/ana.20624
- Jenner P. Oxidative stress in Parkinson’s disease. Annals of Neurology. 2003; 53(Suppl 3): S26-S38. doi: 10.1002/ana.10483
- Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman E, Mizuno Y. Immunohistochemical detection of 4- hydroxynonenal protein adducts in Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(7): 2696-2701. doi: 10.1073/pnas.93.7.2696
- Floor E, Wetzel M. Increased protein oxidation in human SN pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. Journal of Neurochemistry. 1998; 70(1): 268-275. doi: 10.1046/j.1471-4159.1998.70010268.x
- Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, et al. Oxidative DNA damage in the Parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in SN. Journal of Neurochemistry. 1997; 69(3): 1196-1203. doi: 10.1046/j.1471-4159.1997.69031196.x
- Fujita KA, Ostaszewski M, Matsuoka Y, Ghosh S, Glaab E, Trefois C, et al. Integrating pathways of Parkinson's disease in a molecular interaction map. Molecular Neurobiology. 2014; 49(1): 88-102. doi: 10.1007/s12035-013-8489-4
- Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicological Sciences. 2005; 88(1): 193-201. doi: 10.1093/toxsci/kfi304
- Callio J, OuryT, Chu C. Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains. Journal of Biological Chemistry. 2005; 280(18): 18356-18542. doi: 10.1074/jbc.M413224200
- Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nature Reviews of Neuroscience. 2003; 4(5): 365-375. doi: 10.1038/nrn1100
- Perier C, Bové J, Vila M, Przedborski S. The rotenone model of Parkinson’s disease. Trends in Neurosciences. 2003; 26(7): 345-346. doi: 10.1016/S0166-2236(03)00144-9
- Adeleke PA, Annafi OS, Ajayi AM, Ben-Azu B, Okubena O, Umukoro S. Sorghum bicolor-based supplement reduces oxidative stress and pro-inflammatory cytokines to mitigate rotenone-induced Parkinsonian-like motor dysfunctions in rats. Mediterranean Journal of Pharmacy and Pharmaceutical Sciences. 2024; 4(3): 15-26. doi: 10.5281/zenodo.13309953
- Fukushima T, Gao T, Tawara T, Hojo N, Isobe A, Yamane Y. Inhibitory effect of nicotinamide on paraquat toxicity and the reaction site on complex I. Archives of Toxicology. 1997; 71(10): 633-637. doi: 10.1007/s0020 40050437
- Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006; 443(7113): 787-795. doi: 10.1038/nature05292
- Andersen JK. Oxidative stress in neurodegeneration: Cause or consequence? Nature Medicine. 2004; 10 Suppl: S18-S25. doi: 10.1038/nrn1434
- Chandimali N, Bak SG, Park EH, Lim HJ, Won YS, Kim EK, et al. Free radicals and their impact on health and antioxidant defenses: A review. Cell Death Discovery. 2025; 11: 19. doi: 10.1038/s41420-024-02278-8
- Tan BL, Norhaizan ME, Liew WP, Sulaiman Rahman H. Antioxidant and oxidative stress: A mutual interplay in age-related diseases. Frontiers in Pharmacology. 2018; 9: 1162. doi: 10.3389/fphar.2018.01162
- Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative stress: Harms and benefits for human health. Oxidative Medicine and Cellular Longevity. 2017; 2017: 8416763. doi: 10.1155/2017/ 8416763
- Poljšak B, Jamnik P, Milisav I. The importance of a multifaceted approach for accurate and comprehensive evaluation of oxidative stress status in biological systems. Antioxidants. 2025; 14(9): 1083. doi: 10.3390/antiox 14091083
- Haque ME, Akther M, Azam S, Kim IS, Lin Y, Lee YH, et al. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease. British Journal of Pharmacology. 2022; 179(1): 23-45. doi: 10.1111/bph.15684
- Distelmaier F, Koopman WJH, Van Den Heuvel LP, Rodenburg RJ, Mayatepek E, Willems PHGM, et al. Mitochondrial complex deficiency: From organelle dysfunction to clinical disease. Brain. 2008; 132: 833-842. doi: 10.1093/brain/awp058
- Bido S, Soria FN, Fan RZ, Bezard E, Tieu K. Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson’s disease. Scientific Reports. 2017; 7: 7495. doi: 10.1038/s41598-017-07181-0
- Kleele T, Rey T, Winter J, Zaganelli S, Mahecic D, Perreten Lambert H, et al. Distinct fission signatures predict mitochondrial degradation or biogenesis. Nature. 2021; 593: 435-439. doi: 10.1038/s41586-021-03510-6
- Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. PINK1/parkin-mediated mitophagy is dependent on VDAC1 and P62/SQSTM1. Nature Cell Biology. 2010; 12: 119-131. doi: 10.1038 /ncb 2012
- Terešak P, Lapao A, Subic N, Boya P, Elazar Z, Simonsen A. Regulation of PRKN-Independent Mitophagy. Autophagy. 2022; 18: 24-39. doi: 10.1080/15548627.2021.1888244
- Han R, Liu Y, Li S, Li X-J, Yang W. PINK1-PRKN-mediated mitophagy: Differences between in vitro and in vivo models. Autophagy. 2023; 19: 1396-1405. doi: 10.1080/15548627.2022.2139080
- Martínez-Redondo V, Pettersson AT, Ruas JL. The Hitchhiker’s guide to PGC-1α isoform structure and biological functions. Diabetologia. 2015; 58: 1969-1977. doi: 10.1007/s00125-015-3671-z
- Piccinin E, Sardanelli AM, Seibel P, Moschetta A, Cocco T, Villani G. PGC-1s in the spotlight with Parkinson’s disease. International Journal of Molecular Sciences. 2021; 22: 3487. doi: 10.3390/ijms22073487
- Kumar AP, P P, Kumar BRP, Jeyarani V, Dhanabal SP, Justin A. Glitazones, PPAR-γ and neuroprotection. Medicinal Chemistry. 2021; 21: 1457-1464. doi: 10.2174/1389557521666210304112403
- Hahad O, Lelieveld J, Birklein F, Lieb K, Daiber A, Munsell T. Ambient air pollution increases the risk of cerebrovascular and neuropsychiatric disorders through induction of inflammation and oxidative stress. International Journal of Molecular Sciences. 2020; 21(12): 4306. doi: 10.3390/ijms21124306
- Omogunwa TS, Karigidi KO, Akintimehin ES, Didunyemi OM, Ogunbameru FE, Adetuyi FO. Molecular insights into the oxidative stress-inflammation nexus: Review on the mechanisms and consequences for human health. Mediterranean Journal of Medical Research. 2026; 3(3): 265-277. doi: 10.5281/zenodo.22095911
- Schildknecht S, Gerding HR, Karreman C, Drescher M, Lashuel HA, Outeiro TF, et al. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: Implications for disease mechanisms and interventions in synucleinopathies. Journal of Neurochemistry. 2013; 125(4): 491-511. doi: 10.1111/jnc.12226
- Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nature Reviews Disease Primers. 2017; 3(1): 17013. doi: 10.1038/nrdp.2017.13
- Luk KC. Oxidative stress and α-synuclein conspire in vulnerable neurons to promote Parkinson’s disease progression. Journal of Clinical Investigation. 2019; 129(9): 3530-3531. doi: 10.1172/jci130351
- Burtscher J, Millet GP, Place N, Kayser B, Zanou N. The muscle-brain axis and neurodegenerative diseases: The key role of mitochondria in exercise-induced neuroprotection. International Journal of Molecular Sciences. 2021; 22(12): 6479. doi: 10.3390/ijms22126479
- Cacabelos R, Parkinson’s disease: From pathogenesis to pharmacogenomics. International Journal of Molecular Parkinson’s Disease Sciences. 2017; 18(3): 551. doi: 10.3390/ ijms18030551
- Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ. Mitochondrial dysfunction and mitophagy in Parkinson’s disease: From mechanism to therapy. Trends in Biochemical Sciences. 2021; 46(4): 329-343. doi: 10.1016/j.tibs.2020.11.007
- Marino BLB, de Souza LR, Sousa KPA, Ferreira JV, Padilha EC, da Silva CHTP, et al. Parkinson’s disease: A review from pathophysiology to treatment. Medicinal Chemistry. 2020; 20(9): 754-767. doi: 10.2174/13895575 19666191104110908
- Zhao J, Yu S, Zheng Y, Yang H, Zhang J. Oxidative modification and its implications for the neurodegeneration of Parkinson’s disease. Molecular Neurobiology. 2017; 54(2): 1404-1418. doi: 10.1007/s12035-016-9743-3
- Grofik M, Cibulka M, Oleksakova J, Sivak S, Cierny D, Tatarkova Z, et al. Oxidative stress parameters and their relation to motor subtype of Parkinson’s disease and levodopa treatment status. General Physiology and Biophysics. 2023; 42(01): 77-85. doi: 10.4149/gpb_2022051
- Takahashi S, Mashima K. Neuroprotection and disease modification by astrocytes and microglia in Parkinson's disease. Antioxidants. 2022; 11(1): 170. doi: 10.3390/antiox11010170
- Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA. Protective and toxic roles of dopamine in Parkinson’s disease. Journal of Neurochemistry. 2014; 129: 898-915. doi: 10.1111/jnc.12686
- Sossi V, de La Fuente-Fernández R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, Ruth TJ. Increase in dopamine turnover occurs early in Parkinson’s disease: Evidence from a new modeling approach to PET 18 F-Fluorodopa data. Journal of Cerebral Blood Flow Metabolism. 2002; 22: 232-239. doi: 10.1097/00004647-200202000-00011
- Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. International Review of Neurobiology. 2011; 100: 127-149. doi: 10.1016/ B978-0-12-386467-3.00007-8
- Lozano J, Muñoz P, Nore BF, LeDoux S, Segura-Aguilar J. Stable expression of short interfering RNA for DT-diaphorase induces neurotoxicity. Chemical Research in Toxicology. 2010; 23: 1492-1496. doi: 10.1021/tx 100182a
- Bisaglia M, Mammi S, Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: Analysis of the interactions with α-synuclein. Journal of Biology and Chemistry. 2007; 282: 15597-15605. doi: 10.1074/jbc. M610893200
- Zhou ZD, Lim TM. Dopamine (DA) induced irreversible proteasome inhibition via DA-derived quinones. Free Radical Research. 2009; 43: 417-430. doi: 10.1080/10715760902801533
- Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling of iron overload in brain aging and Parkinson’s disease. Journal of Neurochemistry. 2008; 106: 1866-1875. doi: 10.1111/j.1471-4159.2008.05541.x
- Zhang W, Zecca L, Wilson B, Ren R, Wang Y, Wang X, Hong J-S. Human neuromelanin: An endogenous microglial activator for dopaminergic neuron death. Frontiers in Biosciences. 2013; 5: 1-11. doi: 10.2741/E591
- Cacabelos R. Parkinson’s disease: From pathogenesis to pharmacogenomics. International Journal of Molecular Sciences. 2017; 18: 551. doi: 10.3390/ijms18030551
- Balestrino R, Schapira AHV. Parkinson disease. European Journal of Neurology. 2020; 27: 27-42. doi: 10.1111/ ene.14108
- Guadagnolo D, Piane M, Torrisi MR, Pizzuti A, Petrucci S. Genotype-phenotype correlations in monogenic Parkinson disease: A review on clinical and molecular findings. Frontiers in Neurology. 2021; 12: 648588. doi: 10.3389/fneur.2021.648588
- Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson’s disease: Effect of L-DOPA therapy. Journal of Pharmacology and Experimental Therapy. 1975; 153: 453-464. PMID: 489.
- Nagatsu T, Kato T, Numata Y, Ikuta K, Sano M, Nagatsu I, et al. Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain. Clinica Chimica Acta. 1977; 75: 221-232. doi: 10.1016/0009-8981(77)90193-0
- Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson’s disease: Historical overview and future prospects. Journal of Neural Transmission Supplementum. 2007; 72: 113-120. doi: 10.1007/978-3-211-73574-9_14
- Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Movement Disorders. 2015; 30(1): 4-18. doi: 10.1002/mds.26102
- Nagatsu T, Sawada M. L-DOPA therapy for Parkinson’s disease: Past, present, and future. Parkinsonism Relative Disorders. 2009; 15: S3-S8. doi: 10.1016/S1353-8020(09)70004-5
- Bhat R, Bhat SS, Nisarga P. A systematic review and meta-analysis of traditional Chinese medicine in Parkinsonism. Mediterranean Journal of Medical Research. 2025; 2(4): 169-178. doi: 10.5281/zenodo. 17344302
- Popescu C, Munteanu C, Spînu A, Andone I, Bistriceanu R, Postoiu R, et al. Actual data on essential trace elements in Parkinson’s disease. Nutrients. 2025; 17(11): 1852. doi: 10.3390/nu17111852
- Sium R. Targeting mitochondrial function through clinical foods: Emerging strategies for metabolic diseases. Mediterranean Journal of Medicine and Medical Sciences. 2026; 2(1): 13-18. doi: 10.5281/zenodo.18407685
- Chen Y, Luo X, Yin Y, Thomas ER, Liu K, Wang W, Li X. The interplay of iron, oxidative stress, and α-synuclein in Parkinson's disease progression. Molecular Medicine. 2025; 31(1): 154. doi: 10.1186/s10020-025-01208-3
- Ayton S, Lei P, Hare DJ, Duce JA, George JL, Adlard PA, et al. Parkinson’s disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein. Journal of Neuroscience. 2015; 35(8): 359-3597. doi: 10.1523/JNEUROSCI.3439-14.2015
- Graham JM, Paley MN, Grünewald RA, Hoggard N, Griffiths PD. Brain iron deposition in Parkinson’s disease imaged using the PRIME magnetic resonance sequence. Brain. 2000; 123Pt(12): 2423-2431. doi: 10.1093/brain /123.12.2423
- Costa-Mallen P, Gatenby C, Friend S, Maravilla KR, Hu SC, Cain KC, et al. Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease. Journal of the Neurological Sciences. 2017; 378: 38-44. doi: 10.1016/j.jns.2017.04.035
- Fasano M, Bergamasco B, Lopiano L. Is neuromelanin changed in Parkinson’s disease? Investigations by magnetic spectroscopies. Journal of Neural Transmission. 2006; 113(6): 769-774. doi: 10.1007/s00702-005-0448-4
- Musarò D, Greco M, Lanza M, Damato M, Maffia M. Copper dyshomeostasis affects α-synuclein clearance mechanisms in Parkinson's disease: Insights from in vitro models and translational evidence. International Journal of Molecular Sciences. 2026; 27(7): 2993. doi: 10.3390/ijms27072993
- Sikora J, Ouagazzal AM. Synaptic zinc: An emerging player in Parkinson's disease. International Journal of Molecular Sciences. 2021; 22(9): 4724. doi: 10.3390/ijms22094724
- Chen Q, Hu X, Zhang T, Ruan Q, Wu H. Association between Parkinson disease and selenium levels in the body: A systematic review and meta-analysis. Medicine (Baltimore). 2024; 103(17): e37919. doi: 10.1097/MD. 0000000000037919
- Mattison DR, Momoli F, Alyanak C, Aschner M, Baker M, Cashman N, et al. Diagnosis of manganese and manganese neurotoxicity: A workshop report. Medicine International. 2024; 4(2): 11. doi: 10.3892/mi.2024.135
- Li M, Li Y, Li Y, Zhang C, Lu F, Liu L, Wang H, Ling L, Guo J. Hair metal dysregulation in Parkinson's disease: Implications for diagnosis and gut-brain axis involvement. Science. 2026; 29(3): 114942. doi: 10.1016/ j.isci.2026.114942
- Yesildemir O, Filiz Ozsoz C, Celik MN, Guclu OA, Ozgur A, Ağagündüz D, Budán F. Dietary aluminum exposure is more closely linked to antioxidant dynamics than to body mass index. Toxics. 2025; 13(7): 578. doi: 10.3390/toxics13070578
- Zhou M, Xu K, Ge J, Luo X, Wu M, Wang N, Zeng J. Targeting ferroptosis in Parkinson’s disease: Mechanisms and emerging therapeutic strategies. International Journal of Molecular Sciences. 2024; 25(23): 13042. doi: 10.3390/ijms252313042
- Akyazı O, Korkmaz D, Cevher SC. Experimental Parkinson models and green chemistry approach. Behavioral Brain Research. 2024; 471: 115092. doi: 10.1016/j.bbr.2024.115092
- Li HY, Liu DS, Zhang YB, Rong H, Zhang XJ. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson’s disease. Biophysical Chemistry. 2023; 303: 107122. doi: 10.1016/j.bpc.2023.107122
- Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD. LPO in aging brain and Alzheimer’s disease. Free Radical Biology and Medicine. 2002; 33: 620-626. doi: 10.1016/s0891-5849(02) 00807-9
- Mattson MP. Modification of ion homeostasis by lipid peroxidation: Roles in neuronal degeneration and adaptive plasticity. Trends in Neurosciences. 1998; 20: 53-57. doi: 10.1016/s0166-2236(97)01188-0
- Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ, 2nd, Morrow JD, Montine TJ. Isoprostanes and related products of LPO in neurodegenerative diseases. Chemistry and Physics of Lipids. 2004; 128: 117-124. doi: 10.1016/j.chemphyslip.2003.10.010
- Liu W, Kato M, Akhand AA, Hayakawa A, Suzuki H, Miyata T, Kurokawa K, Hotta Y, Ishiakawa N, Nakashima I. 4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. Journal of Cell Science. 2000; 113: 635-641. doi: 10.1242/jcs.113.4.635
- Schmidt H, Grune T, Müller R, Siems WG, Wauer RR. Increased levels of LPO products malondialdehyde and 4-hydroxynonenal after perinatal hypoxia. Pediatric Research. 1996; 40: 15-20. doi: 10.1203/00006450-19960 7000-00003
Submitted date:
06/22/2026
Reviewed date:
08/22/2026
Accepted date:
08/24/2026
Publication date:
08/27/2026
